Demographic, Clinical, and Para clinical Features in Patients with COVID-19 and ST-Elevation Myocardial Infarction

The aims of this study were to determine the prognosis in heart infarction patients who were also suffering from COVID-19 disease and its relationship with underlying diseases and blood factors and the severity of pulmonary involvement.

This cross-sectional descriptive study extracted data from the medical records of patients hospitalized in Alzahra, Chamran, and Khorsheed hospitals in Isfahan city from 2020 to 2021. Individuals over 18 years old diagnosed with myocardial infarction and positive polymerase chain reaction (PCR) test placed under angiography were included in the study. Variables studied included age, gender, comorbidities, medications, smoking history, vaccination status, laboratory findings, echocardiography, angiography, and mortality. Logistic regression analysis was used to analyze the data.

A total of 65 patients were examined. The most common comorbidity was hypertension (55.4%) and the most common symptom was chest pain (84.6%). Left ventricular ejection fraction decreased (38.2%), and this decrease was significant in patients with ST-elevation myocardial infarction (33.5% vs. 43.7%, P = 0.0009). Thrombosis was observed in 14 patients, which was more common in the ST-elevation myocardial infarction (STEMI) group than in the non-ST-elevation myocardial infarction (NSTEMI) group (30.8% vs. 7.7%, P = 0.03). The most involved artery was LAD (60%). There was no significant association between the severity of COVID-19 and myocardial infarction subtypes. Moreover, these subgroups did not show a significant association with mortality rates.

No significant association was found between the severity of COVID-19 and myocardial infarction subtypes in our study.